

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

761104Orig1s000

MULTI-DISCIPLINE REVIEW

Summary Review

Office Director

Cross Discipline Team Leader Review

Clinical Review

Non-Clinical Review

Statistical Review

Clinical Pharmacology Review

NDA/BLA Multi-disciplinary Review and Evaluation

Application Type	BLA
Application Number(s)	761104
Priority or Standard	Priority
Submit Date(s)	November 30, 2017 and January 29, 2018
Received Date(s)	November 30, 2017 and January 29, 2018
PDUFA Goal Date	September 29, 2018
Division/Office	Division of Hematology Products/Office of Hematology and Oncology Products
Review Completion Date	September 12, 2018
Established Name	Moxetumomab pasudotox
(Proposed) Trade Name	Lumoxiti
Pharmacologic Class	CD22-directed cytotoxin
Code name	CAT-8015
Applicant	AstraZeneca AB
Formulation(s)	Lyophilized powder
Dosing Regimen	0.04 mg/kg administered as a 30-minute intravenous infusion on Days 1, 3, and 5 of each 28-day cycle
Applicant Proposed Indication(s)/Population(s)	Treatment of adult patients with relapsed or refractory hairy cell leukemia who received at least two prior systemic therapies, including with a purine nucleoside analog
Recommendation on Regulatory Action	Approval
Recommended Indication(s)/Population(s) (if applicable)	Treatment of patients with relapsed or refractory hairy cell leukemia who received at least two prior systemic therapies, including a purine nucleoside analog

Table of Contents

Reviewers of Multi-Disciplinary Review and Evaluation	9
Additional Reviewers of Application.....	9
Glossary.....	11
1 Executive Summary	13
1.1. Product Introduction.....	13
1.2. Conclusions on the Substantial Evidence of Effectiveness	13
1.3. Benefit-Risk Assessment	15
1.4. Patient Experience Data.....	18
2 Therapeutic Context	20
2.1. Analysis of Condition.....	20
2.2. Analysis of Current Treatment Options	20
3 Regulatory Background	24
3.1. U.S. Regulatory Actions and Marketing History.....	24
3.2. Summary of Presubmission/Submission Regulatory Activity	24
4 Significant Issues from Other Review Disciplines Pertinent to Clinical Conclusions on Efficacy and Safety.....	25
4.1. Office of Scientific Investigations (OSI)	25
4.2. Product Quality	25
4.3. Clinical Microbiology	26
4.4. Devices and Companion Diagnostic Issues	26
5 Nonclinical Pharmacology/Toxicology.....	27
5.1. Executive Summary.....	27
5.2. Referenced NDAs, BLAs, DMFs.....	29
5.3. Pharmacology.....	29
5.4. ADME/PK	32
5.5. Toxicology.....	32
5.5.1. General Toxicology.....	32
5.5.2. Genetic Toxicology.....	41
5.5.3. Carcinogenicity.....	41
5.5.4. Reproductive and Developmental Toxicology	41
5.5.5. Other Toxicology Studies	42
6 Clinical Pharmacology.....	43

NDA/BLA Multi-Disciplinary Review and Evaluation
BLA 761104, Lumoxiti, Moxetumomab pasudotox

6.1.	Executive Summary	43
6.2.	Summary of Clinical Pharmacology Assessment.....	44
6.2.1.	Pharmacology and Clinical Pharmacokinetics	44
6.2.2.	General Dosing and Therapeutic Individualization.....	45
6.3.	Comprehensive Clinical Pharmacology Review	46
6.3.1.	General Pharmacology and Pharmacokinetic Characteristics.....	46
6.3.2.	Clinical Pharmacology Questions.....	47
7	Sources of Clinical Data and Review Strategy	53
7.1.	Table of Clinical Studies.....	53
7.2.	Review Strategy.....	55
8	Statistical and Clinical and Evaluation	57
8.1.	Review of Relevant Individual Trials Used to Support Efficacy.....	57
8.1.1.	Study CD-ON-CAT-8015-1053	57
8.1.2.	Study Results.....	63
8.1.3.	Assessment of Efficacy Across Trials.....	78
	Study CAT-8015-1053 is the only trial supporting the efficacy of moxetumomab pasudotox in patients with R/R HCL.	78
8.1.4.	Integrated Assessment of Effectiveness.....	78
8.1.5.	Safety Review Approach	80
8.1.6.	Review of the Safety Database	81
8.1.7.	Adequacy of Applicant’s Clinical Safety Assessments	84
8.1.8.	Safety Results.....	85
8.1.9.	Analysis of Submission-Specific Safety Issues.....	94
8.1.10.	Capillary Leak Syndrome	94
8.1.11.	Hemolytic Uremic Syndrome (HUS)	97
8.1.12.	Infusion-related reactions	100
8.1.13.	Hepatic function abnormality.....	102
8.1.14.	Nephrotoxicity	105
8.1.15.	Electrolyte abnormalities	107
8.1.16.	Ocular Toxicity	109
8.1.17.	Fluid Retention	110
8.1.18.	Severe Infections (Including Opportunistic Infections).....	111

NDA/BLA Multi-Disciplinary Review and Evaluation
BLA 761104, Lumoxiti, Moxetumomab pasudotox

8.1.19.	Clinical Outcome Assessment (COA) Analyses Informing Safety/Tolerability	112
8.1.20.	Safety Analyses by Demographic Subgroups	112
8.1.21.	Specific Safety Studies/Clinical Trials	116
8.1.22.	Additional Safety Explorations	116
8.1.23.	Safety in the Postmarket Setting.....	117
8.1.24.	Integrated Assessment of Safety.....	117
8.2.	Statistical Issues	118
8.3.	Conclusions and Recommendations	119
9	Advisory Committee Meeting and Other External Consultations.....	121
10	Pediatrics	122
11	Labeling Recommendations	123
11.1.	Prescription Drug Labeling	123
12	Risk Evaluation and Mitigation Strategies (REMS)	124
13	Postmarketing Requirements and Commitment	125
14	Division Director (DHOT)	126
15	Division Director (OCP)	127
16	Division Director (OB)	128
17	Division Director (Clinical)	129
18	Office Director (or designated signatory authority).....	131
19	Appendices	132
19.1.	References	132
19.2.	Financial Disclosure	133
19.3.	OCP Appendices (Technical documents supporting OCP recommendations).....	134
19.3.1.	Bioanalytical Method Validation and Performance	134
19.3.2.	Clinical Pharmacokinetics and Pharmacodynamics	139
19.3.3.	Immunogenicity.....	145
19.3.4.	Pharmacometrics.....	147
19.4.	Additional Clinical Outcome Assessment Analyses.....	154

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.